Articles by Ben Comer - Pharmaceutical Executive


Articles by Ben Comer

Stem Cells: A Promise Deferred?

Oct 1, 2012

Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures.

The Drug Vote 2012

Oct 1, 2012

A comparative effectiveness study on the two presidential candidates.

The Power of Patient Feedback

Sep 1, 2012

Specialized knowledge about disease and treatment is no longer the exclusive province of practicing physicians. Patient voices are increasing in volume, along with their roles in treatment decisions.

Compliance Kulture: The Facts Behind GSK's CIA

Aug 1, 2012

Big Pharma talks a lot about changing its business model to one that prioritizes quality and value over quantity and waste. While the healthcare "ecosystem" waits for pharma to grow into this model, government is delivering a comeuppance that actually puts it in the driver's seat and gaining the upper hand.

Emerging Pharma Leaders: Eric Dube

Jul 18, 2012

Eric Dube, one of this years Pharm Exec Emerging Pharma Leaders, is not yet 40 and is now GSK's senior VP of strategy after already holding seven "very different" roles at the company.

John Lechleiter on PhRMA and Innovation

Jul 1, 2012

Eli Lilly CEO John Lechleiter on his agenda as incoming chairman of PhRMA, US healthcare reform, the euro crisis, and the small problem, of innovation.

Gamification Grows Up

Jun 1, 2012

Early efforts in the pharma space to harness the engagement factor in game technology focused on delivering a fun experience, with a tackedon educational component. Today's games bring behavior change to the forefront, incorporating social dynamics, mobility, and increasingly sophisticated mechanics.

Raising the Stakes in CNS

Jun 1, 2012

As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.

Disruption in the C-Suite

Jun 1, 2012

Clayton Christensen, author of "The Innovator's Dilemma", offers to collaborate with pharma CEOs on solutions to the strategic impasse around flagging drug productivity.


Click here